StockData
QuidelOrtho Corp logo

QuidelOrtho Corp (QDEL) stock

QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3062% below fair value
$9.87−0.34 (-3.33%)

Close on Nov 17, 2026Market cap $676.84MP/E –Yield –

QuidelOrtho Corp saw revenue fall 4.5% to $2.59B over the twelve months to Sep 27, 2026. Free cash flow was -$117.10M. At the latest close the market valued the company at $676.84M.

Revenue
$2.59B
-4.5% vs. a year earlier
Operating income
-$127.40M
TTM Q3 2026
Free cash flow
-$117.10M
TTM Q3 2026
EPS, diluted
-$5.41
TTM Q3 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 27, 2026

Valuation

Market cap
$676.84M
P/E ratio
–
Price to sales
0.26
Price to book
0.38
Dividend yield
–
Free cash flow yield
-17.30%

Fundamentals

Revenue
$2.59B
Net income
-$369.20M
EPS, diluted
-$5.41
Free cash flow
-$117.10M
Book value per share
$26.07
Diluted shares
69M

Trading

Next earnings
Feb 10, 2027 (estimated, after the close)
Previous close
$10.21
Open
$10.15
Day's range
$9.82 – $10.64
Volume
7,719,583
Average volume (20 days)
2,651,882
Index membership
S&P SmallCap 600 (since Aug 2024), Russell 2000 (since Jun 2025), Russell 3000 (since May 2022)
52-week range
$9.92 – $35.58
RSI (14 days)
36.7
Volatility (1 year)
91.4%
Relative volume
1.10×

On 1 of our idea list: Most shorted (a warning list)

Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodQDELS&P 500DifferenceQDEL per yearS&P 500 per year
1 month-23.5%-4.0%−19.5 pts
3 months-32.3%-5.0%−27.3 pts
Year to date-65.4%+8.2%−73.7 pts
1 year-53.2%+11.2%−64.4 pts
3 years-85.1%+68.5%−153.6 pts-47.0%+19.0%
5 years-93.4%+67.3%−160.7 pts-41.9%+10.8%
10 years-55.5%+291.6%−347.2 pts-7.8%+14.6%

Seven years at a glance

Fiscal years 2019 to 2025 and trailing twelve months, USD

Revenue

$2.59B-4.5% YoY

Gross profit

$1.15B-10.4% YoY

Operating income

-$127.40M

Net income

-$369.20M

EPS, diluted

-$5.41

Free cash flow

-$117.10M
Reported periodTrailing twelve months

Press releases

Releases QuidelOrtho filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About QuidelOrtho

In Vitro & In Vivo Diagnostic Substances

QuidelOrtho Corporation develops diagnostic testing solutions, laboratory instruments, and related services. Its business units comprise Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics, organized geographically into North America, EMEA, China, JPAC, and Latin America. Offerings include clinical chemistry systems, immunoassays, blood typing instruments, donor screening assays, molecular testing platforms, and rapid point-of-care tests, supplemented by informatics software. Customers include hospitals, clinical laboratories, reference labs, physician offices, urgent care and retail clinics, pharmacies, blood banks, donor centers, and over-the-counter consumers.

Company profile, executives and history

QuidelOrtho stock: common questions

What is QuidelOrtho's stock price?

QDEL closed at $9.87 on Nov 17, 2026, down 3.33% on the day. Over the past 52 weeks it traded between $9.92 and $35.58.

What is QuidelOrtho's market cap?

QuidelOrtho was worth $676.84M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is QDEL's P/E ratio?

QuidelOrtho lost money over the twelve months to Sep 27, 2026 (diluted EPS -$5.41), so it has no meaningful P/E ratio.

How much revenue does QuidelOrtho make?

QuidelOrtho reported revenue of $2.59B for the twelve months to Sep 27, 2026, down 4.5% from a year earlier.

Does QuidelOrtho pay a dividend?

No. QuidelOrtho has not paid a cash dividend over the last twelve months.

When does QuidelOrtho report earnings next?

QuidelOrtho is expected to report Q4 FY2026 results on Feb 10, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has QDEL stock performed over the past year?

Including dividends, QDEL returned -53.2% over the past year, against +11.2% for the S&P 500.

How many QDEL shares are sold short?

14M shares were sold short at the latest FINRA report, 37.27% of the float, or 7.6 days of average trading volume.

Who are QuidelOrtho's competitors?

Companies most similar to QuidelOrtho by business, industry and size include IDXX, NEOG, LNTH, QGEN, MYGN.

See a number that looks wrong?